Biotech institute successfully challenges EPO decision revoking key CRISPR patent over priority rights | Appeal follows major ...

Insurance company Cigna claims Bristol Myers Squibb may have caused overpayments of ‘billions’ of dollars after allegedly delaying market entry of generic Pomalyst | Lawsuit follows dismissal of ...

Trio have worked together for several years at different firms, bringing decades of experience in medical devices, robotics, ...

11 January 2022 Alexion, AstraZeneca’s rare disease group, has entered into an exclusive licensing agreement with Neurimmune ...

David Gindler of Orrick discusses the US Supreme Court’s ruling in Amgen v. Sanofi and what it means for ongoing Section 112 ...

Appeals board overturns previous decision and revokes patent on treatment worth $2bn in 2024 | Teva and Generics UK successful in arguing lack of inventive step. Already registered? If you don't have ...